ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
COMPASS Granted Patent of Psilocybin Formulation for Treatment-Resistant Depression
January 17, 2020COMPASS Pathways has been granted US Patent No 10,519,175, relating to methods of treating drug-resistant depression with a psilocybin formulation, by the US Patent and Trademark Office (USPTO). -
COMPASS Pathways Granted Patent Covering Use of Its Psilocybin Formulation in Addressing Treatment-resistant Depression
January 13, 2020George Goldsmith, CEO and Co-founder, COMPASS Pathways, said, "Too many people are suffering with treatment resistant depression. -
Psilocybin study shows positive results in healthy volunteers
December 16, 2019In a new study, COMP360 (psilocybin) was well tolerated in healthy volunteers which support further investigation of a simultaneous 1:1 therapeutic administration design.
Pharma Sources Insight January 2025
